Chester Mathis
Chester A. Mathis | |
|---|---|
| Education | Humboldt State University B.Sc. (1972) UC Davis Ph.D. (1979) |
| Awards | Metlife Foundation Award for Medical Research in Alzheimer's Disease[1] (2004) Potamkin Prize (2008) Reagan Institute Award (2009) |
| Scientific career | |
| Institutions | University of Pittsburgh Medical Center |
Chester Mathis is an American chemist who is currently the Distinguished Professor of Radiology at University of Pittsburgh and holds the UPMC Endowed Chair of PET Research.[2][3][4]
He is known for is work with William E. Klunk on a PET radiotracer for imaging amyloid, a protein linked to neurodegenerative diseases including Alzheimer’s. His efforts led to the creation of a novel category of high-efficacy radiopharmaceutical agents, for example Pittsburgh Compound-B (PiB), which can be used to assess beta-amyloid in the living human brain using PET scanning, and which is a fluorescent analog of thioflavin T.[3] For his work on Alzheimer's disease he has received the Metlife Foundation Award (2004)[5] and the Potamkin Prize (2008).[6]
References
[edit]- ^ "MetLife Foundation Awards for Medical Research in Alzheimer's Disease" (PDF). Archived from the original (PDF) on 13 October 2018.
- ^ "Distinguished Professor". pitt.edu. Retrieved May 4, 2017.
- ^ a b "Chester Mathis". Retrieved May 4, 2017.
- ^ "Chester Mathis". pharmacology.us. Retrieved May 4, 2017.
- ^ "2016 Metlife Foundation Awards for Medical Research in Alzheimer's Disease" (PDF). Metlife Foundation. Archived from the original (PDF) on 13 October 2018. Retrieved 18 October 2018.
- ^ "Awards History". American Academy of Neurology. 23 September 2017. Archived from the original on 23 September 2017. Retrieved 31 October 2018.
| Authority control databases: Academics |
|---|
  | This article about an American scientist in academia is a stub. You can help Wikipedia by expanding it. |